Clinical Trial Update: Study of CEP-701 in Treatment of Prostate Cancer [Phase 2]

View source ↗

Summary

Phase 2 study of CEP-701 (lestaurtinib) for prostate cancer has completed, sponsored by Cephalon.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• CEP-701 (lestaurtinib)

Snippet

Sponsor: Cephalon | Conditions: Prostate Cancer | Phase 2 | Status: COMPLETED